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ABSTRACT 
Introduction: To investigate the relation between left atrial (LA) volume, sphericity and fibrotic 
content derived from contrast-enhanced cardiac magnetic resonance imaging (CE-CMR) 
and their impact on the outcome of catheter ablation for atrial fibrillation (AF).   
Methods and results: In 83 patients undergoing catheter ablation for AF, CE-CMR was used 
to assess LA volume, sphericity and fibrosis. There was a significant correlation between LA 
volume and sphericity (R=0.535, p<0.001) and  between LA volume and fibrosis (R=0.241, 
p=0.029). Multivariate analyses demonstrated that LA volume was the strongest 
independent predictor of AF recurrence after catheter ablation (1.019, p=0.018). 
Conclusion:  Left atrial volume, sphericity and fibrosis were closely related, however LA 
volume was the strongest predictor of AF recurrence after catheter ablation. 
Keywords: Cardiac magnetic resonance; atrial fibrillation ablation, atrial sphericity, left atrial 
volume, atrial fibrosis. 
INTRODUCTION 
Pulmonary vein isolation is a potentially curative treatment option for patients with atrial 
fibrillation (AF).1 However, despite the many technological developments in recent years, the 
success rate of these procedures remains to be wanting.2 Identifying patients that will benefit 
from this treatment is imperative to improve its success rate. Moreover, identification of 
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patients with a low likelihood to benefit from pulmonary vein isolation alone allows the 
electrophysiologist to plan a more comprehensive ablation approach in order to improve the 
outcome.  
Left atrial (LA) remodelling is thought to limit the efficacy of catheter ablation for AF: 
the more diseased the atria are, the less likely a patients is to benefit.3, 4 Traditionally, the 
degree of atrial remodelling was assessed by measurement of the LA diameter.5, 6 Recent 
developments in the field of contrast enhanced cardiac magnetic resonance (CE-CMR) allow 
a more comprehensive characterization of the LA by identification and quantification of LA 
fibrosis and precise measurement of the LA volume and assessment of the LA 
shape/sphericity.7-9  
The aim of the present study is to investigate the relation between LA volume, LA 
sphericity and LA fibrosis in patients with AF, and to examine their relative prognostic impact 
on the outcome of catheter ablation for AF. 
METHODS 
Patient population and study protocol 
The current population comprises a cohort of consecutive patients that underwent CE-CMR 
prior to a first catheter ablation for AF in our institution. Atrial fibrillation was refractory to at 
least one antiarrhythmic drug in all patients, according to the current expert consensus 
statement document. The CE-CMR data was collected prospectively as part of the pre-
procedural evaluation and was retrospectively analyzed to determine LA volume, sphericity 
and fibrotic content. The prognostic impact of these parameters on the outcome of catheter 
ablation for AF was studied. The study protocol was approved by our hospital's ethics 
committee, and written informed consent was obtained from all patients. 
  
 
This article is protected by copyright. All rights reserved. 
3 
 
Contrast Enhanced Cardiac Magnetic Resonance 
Image acquisition 
The acquisition protocol has been reported previously.8 In brief, all studies were obtained on 
a 3-Tesla scanner (Magnetom Trio, Siemens Healthcare, Erlangen, Germany) and a 
dedicated 32-channel cardiac coil. The scan was acquired 20 minutes after injection of an 
intravenous bolus of 0.2 mmol/kg gadobutrol (Gadovist, Bayer Schering Pharma AG, Berlin, 
Germany) using a free-breathing 3D navigator and ECG-gated inversion-recovery gradient-
eco sequence applied in the axial orientation. The voxel size was 1.25x1.25x2.5 mm. 
Repetition time/echo time was 2.3/1.4 ms; flip angle, 11º; bandwidth, 460 Hz/pixel; inversion 
time (TI) 280 to 380 ms; and parallel imaging with GRAPPA technique, with reference lines 
of R=2 and 72. A TI scout sequence was used to nullify the left ventricular myocardial signal 
and determine optimal TI. Typical scan time for a LGE-CMR sequence was 15 minutes 
(range 11-18), depending on heart rate and breathing patterns. 
 
Post-processing 
After data acquisition, all CE-CMR data were exported to the ADAS® program (GALGO 
Medical, Barcelona, Catalunya, Spain) for off-line post-processing. A typical example of the 
post-processing is shown in Figure 1. First, endocardial and epicardial contours of the LA 
were semi-automatically traced in each axial image. Second, in order to minimize 
endocardial and epicardial segmentation artefacts, ADAS® constructed a mid-myocardial 
layer (50% thickness) into a 3D shell of the LA. The mitral valve leaflets were used as 
landmarks to separate the LA from the left ventricle and the LA appendage and the 
pulmonary veins were excluded at their ostia, defined as the site of reflection of these 
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structures with the surrounding LA wall. Next, the signal intensity of the LA wall was 
normalized to the blood pool intensity by calculating the Image Intensity Ratio (IIR) and 
projecting the color-coded values onto the 3D mid-myocardial shell of the LA. Based on 
previous work of our group,8 LA tissue with an IIR > 1.20 was considered as fibrotic tissue. 
ADAS® automatically calculated the size of the fibrotic areas as well as the percentage of the 
LA wall that was fibrotic. The degree of LA fibrosis was classified according to the Utah 
Staging System (UTAH I: ≤5% LA wall enhancement, UTAH II: >5% and ≤20%, UTAH III: 
>20% and ≤35%, UTAH IV: >35%).9 
Finally, the software calculated the LA volume and LA sphericity from the 3D shell. 
The LA sphericity is a measure for the difference in shape between the actual LA and a 
theoretical sphere-shaped LA.7 The radius of this theoretical sphere equals the average 
radius (AR) between the endocardial borders and the centre of mass of the actual LA. To 
determine the LA sphericity, the AR and the standard deviation of the AR are used to 
calculate the coefficient of variation (AR standard deviation/AR). Successively, LA sphericity 
is calculated using the following formula [(1 – coefficient of variation) x 100]. All analyses 
were performed blinded to the clinical parameters. 
A perfect sphere-shaped LA has a sphericity value of 100, with lower values for those 
atria adopting non-spherical contours. It is thought that the remodelling process involves a 
progressive change in atrial morphology that evolves from discoid-shaped to sphere-shaped, 
thereby progressively increasing the sphericity value. Previous work by our group has shown 
that a high LA sphericity value is associated with a higher risk for AF recurrence after 




This article is protected by copyright. All rights reserved. 
5 
 
All ablation procedures were performed under deep sedation. After venous access through 
the femoral vein, a double transseptal puncture was performed to acquire access to the LA. 
A bolus of heparin (5000-6000 IU, according to patient weight) was then administered, as 
well as an additional bolus, to maintain an acitivated clotting time of 250-300 s. A circular 
mapping catheter (LASSO®, Biosense Webster, Daimond Bar, CA, USA) was introduced 
inside the LA to assess pulmonary vein conduction. 
Catheter ablation was either performed using radiofrequency or a cryoballoon. Both 
procedures have been described previously.7, 11 In brief, during the procedures with a 
cryoballoon, the catheter (Arctic Front, Medtronic, Minneapolis, MN, USA) was positioned 
inside each pulmonary vein antrum selectively using fluoroscopy. After confirmation of 
adequate occlusion, the balloon was filled with a liquid refrigerant during a 5-minute 
application. After application, pulmonary vein conduction was checked and additional 
applications were delivered until pulmonary vein isolation was confirmed.  
During radiofrequency catheter ablation, two circular lesions were created around the 
ipsilateral left and right pulmonary vein ostia using a non-fluoroscopic mapping system 
(CARTO 3™, Biosense Webster). Radiofrequency current was applied by a 3.5 mm open-
irrigation catheter (NaviStar™, Biosense Webster) at a target temperature of 45°C and a 
maximum output of 40 W until pulmonary vein isolation was confirmed. In order to reduce 
the risk of oesophageal complications, power was reduced to 35 W in the posterior wall and 
RF application was limited to 10 to 20 seconds per point. Additional ablation lesions (e.g., 
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The procedural endpoint for both techniques was pulmonary vein isolation 
demonstrated by bidirectional block on the circular mapping catheter or entrance block when 
local capture inside the pulmonary vein could not be confirmed. 
 
Follow-up 
After ablation, all patients were evaluated on a regular basis at the outpatient clinic (1, 3, 6 
and 12 months). ECG recordings were acquired each visit as well as 24-hour ECG Holter 
monitoring. In addition to these routine visits, patients were encouraged to immediately 
obtain an ECG registration when experiencing palpitations. After a blanking period of 3 
months, recurrence of AF was defined as any recording of AF on ECG or an episode longer 
than 30 s on 24-hour ECG Holter registration.1  
Statistical analyses 
All variables were tested for a normal distribution with the Shapiro-Wilk test. Normally 
distributed continuous variables are represented as mean ± SD and non-normally distributed 
continuous variables are represented as median (Interquartile Range [IQR]). Categorical 
variables are presented as number (percentage). Statistical comparisons for continuous 
variables were performed with the Student t test or with the Mann-Whitney U test as 
appropriate. Statistical comparisons for categorical variables were performed with the Chi-
square test. Univariable Cox proportional hazard analyses were performed to investigate the 
impact of LA volume, sphericity and fibrotic content on the recurrence of AF after ablation. 
The variables with a P <0.1 in the univariable analysis were included in the multivariable 
analysis. Multivariable analysis was performed using a backward Wald stepwise method 
(variables with P >0.1 were removed from the model). For the multivariate analysis, we use 
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the P/10 rule to avoid overfitting in the final model. Receiver operator characteristic curve 
analysis was performed to determine the optimal cut-off value for the strongest independent 
predictor to predict AF recurrence, based on the highest combined sensitivity and specificity. 
Furthermore, Kaplan-Meier plots were created and the log-rank test was performed to test 
the difference in AF recurrence after ablation using these cut-off values. All statistical 
analyses were performed with SPSS software (version 23.0, IBM Corporation, Armonk, NY, 
USA). A value of P< 0.05 was considered statistically significant. 
RESULTS 
A total of 83 patients [64 men (77%), mean age 55.8 ± 10.1 years] were included in this 
study. Baseline characteristics are shown in Table 1. The median duration of AF was 36 
months (IQR 34). Atrial fibrillation was paroxysmal in 43 patients (52%), persistent in 38 
patients (46%) and longstanding persistent in 2 patients (2%), according to current 
guidelines definitions.12 In 73 patients (87%) ablation was performed using a radiofrequency 
catheter and in 10 patients (12%) using a cryoballoon catheter. The procedural endpoint of 
pulmonary vein isolation was reached in all patients. No major procedural complications 
were observed, while minor complications occurred in 5 patients (Table 1).  
LA volume, sphericity and fibrotic content 
The median LA volume on CMR was 94.4 ml (IQR 43.8), mean LA sphericity was 79.2 ± 3.2 
and median LA fibrotic content was 6.2 cm2 (IQR 8.9), corresponding to a median 6.0% (IQR 
6.7) of the LA surface.  
The LA volume was significantly higher in patients with non-paroxysmal AF versus 
paroxysmal AF (105.6 [IQR 51.4] versus 86.5 ml [IQR 37.5], p=0.001). The LA sphericity 
was similar between patients with non-paroxysmal and paroxysmal AF (79.4 ± 3.5 versus 
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79.0 ± 3.0, p=0.550). The absolute amount of LA fibrotic content was higher in patients with 
non-paroxysmal AF compared to paroxysmal AF (8.4 cm2 [IQR 9.1] versus 5.0 cm2 [IQR 
6.8], p=0.039), but the percentage of LA fibrosis relative to the LA surface was not 
significantly different (6.8% [IQR 8.0] in non-paroxysmal versus 5.7% [IQR 5.2] in 
paroxysmal, p=0.264). There was an intermediate correlation between LA volume and LA 
sphericity (R=0.535, p<0.001, Figure 2, panel A). Furthermore, a weak but significant 
correlation was found between LA volume and LA fibrotic content (R=0.241, p=0.029, Figure 
2, panel B). 
Follow-up after catheter ablation 
After a follow-up of 12 month, 60 patients (72%) had maintained stable sinus rhythm after a 
mean of 1.3  0.6 procedures. The success rate after one ablation procedure was 57%.  At 
12 months of follow-up, antiarrhythmic drugs had been discontinued in 48 patients (80%) 
with stable sinus rhythm. There was no difference in the recurrence rate between 
radiofrequency catheter ablation and cryoballoon ablation (30% versus 10%, respectively, 
p=0.182). Moreover, there was no significant difference in recurrence rate between patients 
without additional ablation lesions, patients with additional linear lesions and patients with 
both additional linear lesions as well as CFAE (23% versus 37% versus 38%, respectively, 
p=0.419). Univariable Cox regression analyses (Table 2) showed that LA volume was 
significant predictor of AF recurrence after ablation (HR 1.024, p<0.001). Furthermore, LA 
sphericity had a significant prognostic impact on the efficacy of catheter ablation (HR 1.187, 
p=0.030). There was no significant relation between the absolute amount of LA fibrosis and 
AF recurrence (HR 1.026, p=0.210). However, there was a tendency towards a higher risk 
for AF recurrence in patients with UTAH IV stage LA fibrosis (HR 4.015, p=0.062). Non-
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paroxysmal AF was associated with a higher risk for AF recurrence (HR 3.006, p=0.016). No 
other parameters predicted AF recurrence. 
Multivariate analyses demonstrated that that LA volume was the strongest and only 
independent predictor of AF recurrence after catheter ablation (Table 3). ROC analyses 
demonstrated that the optimal cut-off value for LA volume to predict AF recurrence was 93.0 
ml: area under the curve of 0.680 (p = 0.013), sensitivity of 0.70, specificity of 0.57, positive 
predictive value of 0.38 and negative predictive value of 0.83 (Figure 3). 
DISCUSSION 
The present study investigated the impact of LA volume, sphericity and fibrotic content on 
the outcome of catheter ablation for AF. Our results demonstrate that these LA remodelling 
markers are closely associated with each other. The most important finding of this study is 
that, despite this close association, LA volume is the strongest independent predictor of AF 
recurrence after catheter ablation. 
Left atrial structural remodelling 
Left atrial remodelling is a complex process of structural and electrical changes that 
determines the susceptibility of the heart to develop and perpetuate AF.13, 14 A higher extent 
of LA remodelling limits the efficacy of catheter ablation for AF.3, 4 Therefore, markers of LA 
remodelling have been used to predict the outcome of catheter ablation for AF by different 
groups.4, 5 
Left atrial dilatation is one of the hallmarks of LA remodelling and has been long 
since recognized as a predictor of AF recurrence after catheter ablation. More recently, LA 
sphericity and LA fibrosis were reported to yield additive information leading to a more 
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comprehensive assessment of LA remodelling and eventually improvement of the prediction 
of AF recurrence after ablation.7, 9  
The present study demonstrated that there is a clear association between LA 
volume, LA sphericity and LA fibrosis: a higher extent of LA dilatation is related to a more 
sphere-shaped LA with a higher degree of fibrosis. Nevertheless, these associations are of 
a weak to moderate intensity, suggesting that to a certain extent they reflect different 
processes contributing to atrial remodelling. This is in agreement with computational models 
that demonstrated that both atrial dilation and fibrotic content independently contribute to 
structural remodelling of the atria and the incidence of AF.15, 16 Atrial morphology as a sign 
of remodelling has also been studied,17 but clear proof of a direct arrhythmogenic effect is 
still lacking.  
Currently it is unclear whether LA volume, LA sphericity and LA fibrotic content follow 
a linear relationship during the process of atrial remodeling. There are suggestions that this 
might not be the case.18 In agreement with these findings, the current population contained 
a subgroup of patients with a remarkable high degree of LA fibrosis in the presence of non- 
or mildly dilated atria (Figure 2B). Our results demonstrate that LA volume was a stronger 
predictor of AF recurrence after catheter ablation than LA sphericity and LA fibrosis. To our 
knowledge, this is the first time that the relation between these markers of LA remodelling is 
studied, as well as their relative impact on the outcome of catheter ablation for AF.  
Previous work by Bisbal et al also demonstrated that there is a relation between LA 
dilatation and LA sphericity.7 Different to our study, they found that LA sphericity was a 
stronger predictor of AF recurrence than LA volume. However, in their study the mean LA 
volume was considerably smaller than in the present study (81.8 ± 26 ml versus 94.4 ml 
[IQR 43.8 ml]), likely reflecting AF patients at an earlier stage and with less remodelled atria. 
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These results suggest that LA sphericity has an important prognostic impact only in 
moderately diseased atria, whereas LA volume is more important in patients with a more 
advanced stage of atrial disease.   
In contrast, Marrouche et al. demonstrated that LA fibrosis only limits the efficacy of 
catheter ablation for AF in patients with a severely diseased LA with a high degree of fibrotic 
content (UTAH IV) but not in patients with an intermediate or low degree of LA fibrosis.9 In 
the present study, only 3 patients (4%) demonstrated a UTAH IV degree of LA fibrosis. The 
low prevalence of a high amount of fibrosis in the present population could be an 
explanation why the amount of LA fibrotic content failed to reach statistical significance. 
Limitations 
The current study represents a consecutive group of patients who underwent CE-CMR prior 
to a catheter ablation for AF, when CE-CMR was available. Additional research should be 
performed to confirm these results. Moreover, there could be a different prognostic impact of 
LA volume, LA sphericity and LA fibrotic content on the outcome of AF ablation in patients 
with relatively less remodelled atria than in severely diseased atria. Since the prevalence of 
severely diseased atria with a high degree of fibrosis (UTAH IV) is relatively low, the current 
study is most likely underpowered to demonstrate the prognostic impact of fibrotic content 
on the outcome of AF ablation. Therefore, further studies should be performed in patients 
with different stages of atrial disease before drawing final conclusions. Furthermore, the 
detection of AF recurrence after catheter ablation was based on Holter registrations 
acquired on a systematic basis. Importantly, patients were encouraged to obtain an ECG 
registration when experiencing palpitations in order to confirm AF as the cause of these 
complaints. Nevertheless, asymptomatic episodes may have been missed. 
  
 




Left atrial volume, LA sphericity and LA fibrotic content are closely related. However, LA 
volume is the strongest independent predictor of AF recurrence after catheter ablation. 
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TABLES 
Table 1. Baseline  
Baseline characteristics Population (n=83) 
Age (years)  55.8 ± 10.1 
Male gender, n (%) 64 (77%) 
Body surface area (m2) 2.00 ± 0.21 
Duration of AF (months)  36 (IQR 34) 
Non-paroxysmal AF, n (%) 40 (48%) 
Hypertension, n (%) 44 (53%) 
Obstructive sleep apnea syndrome, n (%) 11 (13%) 
LA anterior-posterior diameter (mm) 42.8 ± 5.2 
LA volume (ml) 94.4 (IQR 43.8) 
Left ventricular ejection fraction (%)  58.6 ± 7.4 
LA sphericity  79.2 ± 3.2 
LA fibrotic content (cm2) 6.2 (IQR 8.9) 
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LA fibrotic content classification  
 UTAH I (<5% of LA surface), n (%)  31 (37%) 
 UTAH II (5-20% of LA surface), n (%) 46 (55%) 
 UTAH III (20-35% of LA surface), n (%) 3 (4%) 
 UTAH IV (>35% of LA surface), n (%) 3 (4%) 
  
Failed antiarrhythmic drugs  
Class IC antiarrhythmic drug, n (%) 46 (55%) 
Amiodarone, n (%) 37 (45%) 
Sotalol, n (%) 6 (7%) 
  
Procedural characteristics  
Radiofrequency, n (%) 73 (88%) 
Cryoballoon, n (%) 10 (12%) 
Additional lesions, n (%) 27 (33%) 
- Linear lines, n (%) 19 (23%) 
- Linear lesions and CFAE, n (%) 8 (10%) 
  
 





- Pericarditis, n (%) 1 (1%) 
- Femoral hematoma, n (%) 2 (2%) 
- Femoral pseudoaneurysm, n (%) 3 (4%) 
- Femoral arteriovenous fistula, n (%) 1 (1%) 
 
Table 2. Cox univariable proportional hazard analyses of clinical and magnetic 
resonance imaging characteristic to predict AF recurrence after catheter ablation 
 HR 95% CI P-value 
Age, per year 1.009 0.966 – 1.055 0.674 
Male gender 0.804 0.317 – 2.039 0.645 
Body surface area, per m2 1.112 0.138 – 8.982 0.921 
Duration of AF, per month  1.004 0.992 – 1.016 0.531 
Non-paroxysmal AF 3.006 1.233 – 7.328 0.016 
Hypertension 0.716 0.315 – 1.623 0.423 
LA volume, per ml 1.024 1.010 – 1.039 <0.001 
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LA sphericity, per unit 1.187 1.017 – 1.385 0.030 
LA fibrotic content    
 per cm2 1.026 0.986 – 1.067 0.210 
 UTAH IV 4.015 0.933 – 17.281 0.062 
Left ventricular ejection fraction, per % 1.017 0.954 – 1.084 0.600 
 
Table 3. Cox multivariable proportional hazard analyses of clinical and magnetic 
resonance imaging characteristic to predict AF recurrence after catheter ablation. 
 Step 1 Step 2 Step 3 
 HR P-value HR P-value HR P-value 
Non-paroxysmal AF 2.325 0.115 2.158 1.141 2.327 0.101 
LA volume, per ml 1.013 0.171 1.019 0.018 1.019 0.018 
UTAH IV fibrosis 2.478 0.239 2.551 0.222 - - 
LA sphericity, per unit 1.093 0.321 - - - - 
 
FIGURE LEGENDS 
Figure 1. After acquisition, all CE-CMR data were exported to the ADAS® program for off-
line post-processing (panel A). After semi-automatic tracing of the endocardial and epicardial 
contours, the system constructed a mid-myocardial layer in which it calculated the signal 
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intensity of the LA wall normalized to the blood pool intensity (IIR) (panel B). A 3D shell of 
the mid-myocardial layer was created that was color-coded according to the IIR (panel C). 
From this 3D shell the LA volume, LA sphericity and LA fibrotic content were calculated 
(panel D). 
 
Figure 2. Scatter plots showing the correlation of left atrial sphericity (panel A) and left atrial 
fibrotic content (panel B) with left atrial volume. 
  
 









This article is protected by copyright. All rights reserved. 
22 
 
Figure 3. Kaplan–Meier curve for freedom of atrial fibrillation (AF) after catheter ablation 
according to left atrial volume < 93.0 ml or ≥ 93.0 ml. 
 
 
